Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness - PubMed (original) (raw)
. 1994 Sep;145(3):702-14.
Affiliations
- PMID: 8080050
- PMCID: PMC1890319
Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness
M Hsiao et al. Am J Pathol. 1994 Sep.
Abstract
Leukemia cell infiltration and the induction of lethal hematopoietic disease in immune-deficient SCID mice transplanted with human T cell acute lymphoblastic T leukemia (T-ALL) cells occurred only when the cells possessed mutant p53 genes and lacked a wild-type allele or when T-ALL cells lacking p53 protein were infected with specific mutant p53 genes. A series of six mutant p53 genes were cloned from relapse T-ALL-derived cell lines and were constructed into defective retroviral expression vectors. Viruses encoding mutant p53 proteins were used to infect relapse T-ALL cells in a study designed to compare their pathogenic potency. The mutant p53 genes possessed a distinct hierarchy in vivo and in vitro: mutants inducing the greatest increase in proliferation of different T-ALL lines in vitro and colony formation in methylcellulose cultures also induced tissue invasiveness of infected T-ALL cells in vivo. Mutant p53 gene transfer to a cell line lacking p53 protein showed that the more potent p53 mutants possessed a distinctive dominant oncogenic activity in vitro and in vivo. The dominant oncogenic activity of these mutant p53 proteins was not dependent on the presence of and on complex formation with wild-type p53 protein. These "hot" p53 mutations thus represent bona fide gain-of-function mutations. Infection of p53-negative T-ALL cells with viruses encoding gain-of-function mutant p53 genes resulted in the acquisition of metastatic potential and tissue invasiveness. Taken together, our results suggest that specific mutant p53 genes play a role in the generation of lymphohematopoietic metastatic potential and tissue invasiveness as assayed in SCID mice, whereas the expression of wild-type p53 is capable of keeping this metastatic potential in check.
Similar articles
- Dissemination and tissue invasiveness in murine acute leukemia associated with acquisition of p53 mutation and loss of wild-type p53.
Hsiao M, Wu CY, Low J, Pattengale P, Yeargin J, Haas M. Hsiao M, et al. Mol Carcinog. 1995 Jun;13(2):112-21. doi: 10.1002/mc.2940130208. Mol Carcinog. 1995. PMID: 7605579 - Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene.
Cheng J, Yee JK, Yeargin J, Friedmann T, Haas M. Cheng J, et al. Cancer Res. 1992 Jan 1;52(1):222-6. Cancer Res. 1992. PMID: 1727382 - P53 mutation in acute T cell lymphoblastic leukemia is of somatic origin and is stable during establishment of T cell acute lymphoblastic leukemia cell lines.
Yeargin J, Cheng J, Yu AL, Gjerset R, Bogart M, Haas M. Yeargin J, et al. J Clin Invest. 1993 May;91(5):2111-7. doi: 10.1172/JCI116435. J Clin Invest. 1993. PMID: 8486778 Free PMC article. - P53-mediated radioresistance does not correlate with metastatic potential in tumorigenic rat embryo cell lines following oncogene transfection.
Bristow RG, Brail L, Jang A, Peacock J, Chung S, Benchimol S, Hill RP. Bristow RG, et al. Int J Radiat Oncol Biol Phys. 1996 Jan 15;34(2):341-55. doi: 10.1016/0360-3016(95)02023-3. Int J Radiat Oncol Biol Phys. 1996. PMID: 8567335 Review. - Mutant p53 gain of oncogenic function: in vivo evidence, mechanism of action and its clinical implications.
Adhikari AS, Iwakuma T. Adhikari AS, et al. Fukuoka Igaku Zasshi. 2009 Jun;100(6):217-28. Fukuoka Igaku Zasshi. 2009. PMID: 19670804 Review.
Cited by
- Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
Jiang D, Dumur CI, Massey HD, Ramakrishnan V, Subler MA, Windle JJ. Jiang D, et al. PLoS One. 2015 Feb 19;10(2):e0118029. doi: 10.1371/journal.pone.0118029. eCollection 2015. PLoS One. 2015. PMID: 25695772 Free PMC article. - Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.
Mandal CC, Ghosh-Choudhury N, Yoneda T, Choudhury GG, Ghosh-Choudhury N. Mandal CC, et al. J Biol Chem. 2011 Apr 1;286(13):11314-27. doi: 10.1074/jbc.M110.193714. Epub 2011 Jan 3. J Biol Chem. 2011. PMID: 21199873 Free PMC article. - The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.
Eischen CM, Lozano G. Eischen CM, et al. Hum Mutat. 2014 Jun;35(6):728-37. doi: 10.1002/humu.22524. Epub 2014 Mar 6. Hum Mutat. 2014. PMID: 24488925 Free PMC article. Review. - An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control.
Gualberto A, Aldape K, Kozakiewicz K, Tlsty TD. Gualberto A, et al. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5166-71. doi: 10.1073/pnas.95.9.5166. Proc Natl Acad Sci U S A. 1998. PMID: 9560247 Free PMC article. - Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene.
Gorgoulis VG, Zacharatos PV, Manolis E, Ikonomopoulos JA, Damalas A, Lamprinopoulos C, Rassidakis GZ, Zoumpourlis V, Kotsinas A, Rassidakis AN, Halazonetis TD, Kittas C. Gorgoulis VG, et al. Br J Cancer. 1998;77(3):374-84. doi: 10.1038/bjc.1998.60. Br J Cancer. 1998. PMID: 9472631 Free PMC article.
References
- Am J Pathol. 1982 Jun;107(3):362-77 - PubMed
- Oncogene. 1990 Jul;5(7):973-80 - PubMed
- Genes Chromosomes Cancer. 1992 Jan;4(1):1-15 - PubMed
- Nature. 1992 May 7;357(6373):82-5 - PubMed
- Proc Natl Acad Sci U S A. 1988 Sep;85(17):6460-4 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous